Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824583 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL14488388 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL19389900 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL193274 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL20811615 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL204377 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL14488570 | 0.85 | NR1H2 (0.42) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL18084469 | 0.85 | NR1H2 (0.42) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL30396554 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL9003564 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2024-08-15 | — | — | US | disclosed |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| EP-2454252-B1 | Spiro amino compounds suitable for the treatment of (inter alia) sleep disorders and drug addiction | Rottapharm Biotech Srl (IT) | 2015-03-04 | — | — | EP | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| US-8859608-B2 | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-10-14 | — | — | US | disclosed |
| EP-2454252-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | Rottapharm S.p.A. (IT) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM BIOTECH S.R.L. (IT) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011006960-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | ROTTAPHARM S.P.A. (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | HSD17B10 856/4885SMN1; SMN2 2971/4885EPHX2 1759/4885 |
| US-20240270693-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | HSD17B10 1711/4885SMN1; SMN2 4032/4885EPHX2 1581/4885 |
| US-20120115882-A1 | SPIRO AMINO COMPOUNDS SUITABLE FOR THE TREATMENT OF INTER ALIA SLEEP DISORDERS AND DRUG ADDICTION | SLC1A1, SLC6A3, SLC1A2 | HSD17B10 1254/4885SMN1; SMN2 1894/4885EPHX2 2465/4885 |
| US-20240270721-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | HSD17B10 966/4885SMN1; SMN2 3879/4885EPHX2 1075/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | HSD17B10 966/4885SMN1; SMN2 3879/4885EPHX2 1075/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | HSD17B10 1711/4885SMN1; SMN2 4032/4885EPHX2 1581/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | HSD17B10 1162/4885SMN1; SMN2 3613/4885EPHX2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.